Relapse of Cutaneous Fungal Infection in Healthy Individuals - A Rising Concern

Ahmed, Sheikh Manzoor; Jeelani, Shazia; Lanker, Audil Mohmad; Qayoom, Seema; Sameem, Farah

doi:10.9734/bjmmr/2016/21634

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[161718] In India, we are presently noticing a significant rise in number of dermatophytosis cases with chronic recalcitrant disease, atypical presentations, frequent relapses, and treatment failures. [19202122] Though the reason for this phenomenon is not yet clear, it is assumed that unchecked availability of cheap and irrational fixed-dose corticosteroid–antifungal–antibacterial combinations sold over the counter in India and in-vitro resistance to common antifungals (to some extent) is playing a pivotal role. Due to recent increase in the reports of antifungal drug resistance in dermatophytes, many groups have suggested to perform the antifungal drug susceptibility testing especially for the dermatophytes isolated from chronic/recurrent/recalcitrant cases or those with atypical presentations.…”

mentioning

confidence: 99%

Antifungal drug susceptibility testing of dermatophytes: Laboratory findings to clinical implications

Dogra

Shaw

Rudramurthy

2019

Indian Dermatol Online J

View full text Add to dashboard Cite

mentioning

confidence: 99%

Antifungal drug susceptibility testing of dermatophytes: Laboratory findings to clinical implications

Dogra

Shaw

Rudramurthy

2019

Indian Dermatol Online J

View full text Add to dashboard Cite

“…As such, SFIs are frequently misdiagnosed and inappropriately treated, which may in turn complicate subsequent management and increase the overall burden of care [9,10]. Although controlled trials showed that existing treatments are efficacious when the SFI is correctly diagnosed and treatment guidelines are followed [9], persistent challenges such as poor compliance and infection recurrence remain obstacles to real-world SFI management [11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Towards Better CARE for Superficial Fungal Infections: A Consultation Guide for the Community Pharmacy

et al. 2022

View full text Add to dashboard Cite

Superficial fungal infections (SFIs) are among the most common skin diseases worldwide and are common in many parts of Asia. Community pharmacists are well-placed to help identify and manage SFIs. However, effective management may be hindered by a suboptimal consultation process, attributed to the misalignment between consumers’ and pharmacists’ viewpoints. The Fungal CARE (Care, Assess, Recommend, Empower) guide, a patient-centered collaborative framework, was developed to improve pharmacist-led SFI consultations in community pharmacy. A survey on real-world consumer experiences with SFIs provided insights for aligning the Fungal CARE guide with consumer perspectives. To further optimize the guide, community pharmacists were surveyed on their current practice and challenges of managing SFIs, as well as views on the usefulness of the Fungal CARE guide. The pharmacists’ survey indicated that respondents engaged with some but not all of consumers’ top concerns with SFIs, such as emotional and social aspects. Pharmacists identified their greatest challenges as poor compliance with SFI treatment and limited confidence in identifying and/or managing SFIs. Encouragingly, when presented with the Fungal CARE guide, nearly all pharmacists agreed it would be helpful and would use it in practice. Implementing the Fungal CARE guide may help improve pharmacist-led consultations for SFIs and encourage better treatment outcomes.

show abstract

Fungal coexistence in the skin mycobiome: a study involving Malassezia, Candida, and Rhodotorula

Naik,

Sasikumar,

et al. 2024

AMB Expr

View full text Add to dashboard Cite

Evidence of fungal coexistence in humans points towards fungal adaptation to the host environment, like the skin. The human commensal Malassezia has evolved, especially residing in sebum-rich areas of the mammalian body where it can get the necessary nutrition for its survival. This fungus is primarily responsible for skin diseases like Pityriasis versicolor (PV), characterized by hypo or hyperpigmented skin discoloration and erythematous macules. In this manuscript, we report a 19-year-old healthy female who presented with a one-year history of reddish, hypopigmented, asymptomatic lesions over the chest and a raised erythematous lesion over the face. Upon clinical observation, the patient displayed multiple erythematous macules and erythematous papules over the bilateral malar area of the face, along with multiple hypopigmented scaly macules present on the chest and back. Based on the above clinical findings, a diagnosis of PV and Acne vulgaris (AV) was made. Interestingly, the patient was immunocompetent and didn’t have any comorbidities. Upon isolation of skin scrapings and post-culturing, we found the existence of three fungal genera in the same region of the patient’s body. We further went on to confirm the identity of the particular species and found it to represent Malassezia, Rhodotorula, and Candida. We report how Malassezia, the predominant microbial resident skin fungus, coexists with other fungal members of the skin mycobiome. This study on an applied aspect of microbiology also shows how important it is to identify the fungal organism associated with skin infections so that appropriate therapeutics can be advised to avoid cases of relapse.

show abstract

Relapse of Cutaneous Fungal Infection in Healthy Individuals - A Rising Concern

Cited by 3 publications

References 28 publications

Antifungal drug susceptibility testing of dermatophytes: Laboratory findings to clinical implications

Antifungal drug susceptibility testing of dermatophytes: Laboratory findings to clinical implications

Towards Better CARE for Superficial Fungal Infections: A Consultation Guide for the Community Pharmacy

Fungal coexistence in the skin mycobiome: a study involving Malassezia, Candida, and Rhodotorula

Contact Info

Product

Resources

About